^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    givastomig (TJ-CD4B)

    i
    Other names: TJ-CD4B, ABL111, TJ-CLDN4B, TJ033721, ABL 111, TJ 033721, TJ CD4B, TJ CLDN4B, ABL-111, TJ-033721, TJCD4B, TJCLDN4B
    Company:
    ABL Bio, I-Mab
    Drug class:
    CLDN18.2 inhibitor, CD137 agonist
    Related drugs:
    Apply
    Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors (NCT04900818)
    Phase 1
    I-Mab Biopharma US Limited
    Recruiting
    Last update posted :
    01/03/2025
    Initiation :
    06/29/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    PD-L1 • CLDN18
    |
    CLDN18.2 positive
    |
    Opdivo (nivolumab) • givastomig (TJ-CD4B)